7DC.F DACHA STRATEGIC

Healthcare Biotechnology Frankfurt Exchange
2.12 EUR
Close of Nov 12, 2026
1.39 2.40
Market cap
EUR 180M
P/E
-
P/B
4.17x
ROE
0.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 7DC.F undervalued?

Graham number

The Graham number of DACHA STRATEGIC cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

DACHA STRATEGIC fundamental analysis

No fundamental analysis for DACHA STRATEGIC yet.

DACHA STRATEGIC stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About DACHA STRATEGIC

Diaceutics PLC, a diagnostic commercialization company, provides data, data analytics, and implementation services for pharma and biotech companies. The company offers DXRX, a diagnostic commercialization platform for precision medicine that integrates multiple pipelines of diagnostic testing data from a network of laboratories. It also provides DXRX data solutions, including DXRX Signal, that enables potential therapy eligibility for patients within hours of a diagnostic ev…

Full company profile